ClinicalTrials.gg
CompletedNCT00353691Updated Jan 11, 2011

Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of glimepiride and metformin in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
29th of 52
100 · median 169
Started
2002
with 1 other
Phase 3
18 of 52
1 open now
Registered
7th of 52
by date
Lead sponsor
9 of 52
Sanofi

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 2 that started in 2002, is one of 18 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To compare the change in glycemic control from baseline to endpoint (last available posttreatment assessment) as measured by HbA1c in pediatric subjects with type 2 diabetes receiving either glimepiride or metformin as monotherapy.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who had type 2 diabetes treated with diet and exercise only for at least 2 weeks prior to randomization, or who were previously or currently treated with an oral agent and had not responded to diet, exercise, and oral therapy for at least 3 months (documented by an >7.5%).
  2. Subjects who completed glimepiride pharmacokinetic Study HOE 490/4045 at preselected sites within 3 weeks prior to the screening period were also permitted to enroll.
  3. Subjects were required to be negative for islet cell antigen (ICA) and glutamic acid decarboxylase (GAD) autoantibodies and to have a C-peptide level at 90 minutes of ≥ 1.5 ng/mL. The HbA1c was required to be >7.1% at screening and \<12.0% on the day of randomization.

Exclusion criteria

EXCLUSION CRITERIA:

Subjects meeting any of the following criteria were not to be included in the study:

  1. A history of an acute metabolic complication such as diabetic ketoacidosis within 3 months before screening
  2. On insulin therapy, or had received insulin for >6 weeks, 3 months prior to randomization
  3. On weight-reduction medication
  4. Known to biguanides, sulfonamides, or insulin
  5. Pregnant or lactating females
  6. renal (serum creatinine level >1.0 mg/dL) or hepatic disease ( [ALT] or aspartate aminotransferase [AST] >2.5 times the [ULN])
  7. GI disorders that may interfere with the absorption of the study drugs
  8. Chronic use of medications known to affect glucose levels such as intermittent use of systemic or large dose of inhaled steroids
  9. Clinically significant laboratory abnormality on screening laboratory tests or any medical condition that in the opinion of the investigator would affect the outcome of the study
  10. History of drug or alcohol abuse
  11. Treatment with any product in the last 3 months before study entry
  12. History of noncompliance with regard to follow-up medical care
  13. Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline to Week 24 or last evaluable ontreatment value.

Secondary outcomes

  1. Change in HbA1c from baseline to Week 12

  2. Responder rate, defined as proportion of subjects with HbA1c < 7.0% at Week 24 or last evaluable on-therapy observation

  3. Mean change in fasting SMBG from baseline to each visit at weeks 4, 8, 12, 18 and 24 or last evaluable on-treatment value.

  4. Mean change in fasting plasma glucose (FPG) from baseline to each visit at weeks 4, 8, 12, 18 and 24 or last evaluable on-treatment value.

  5. Percent completers, defined as subjects who continued study medication until completion of all requirements of Visit 6 (Week 18)

  6. Mean change in lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) from baseline to Wk 24 or last evaluable on-treatment value.

  7. Mean change in body mass index (BMI) from baseline to Wk 12 and Wk 24 or last evaluable on-treatment value

07

Study locations

1 site
  • Sanofi-Aventis
    Bridgewater, New Jersey 08807, United States
08

References and documents

Publications

  • Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007 Apr;30(4):790-4. doi: 10.2337/dc06-1554. PubMed 17392540 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2006
First posted
Jul 19, 2006
Start
Oct 2002
Completion
Nov 2004
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00353691
Lead sponsor
Sanofi
First posted
Jul 19, 2006
Start date
Oct 2002
Completion
Nov 2004
Last update
Jan 11, 2011

Study contacts

Karen Barch, B.S.
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Metformin

Start the discussion